Advancis drug fails again

Advancis Pharmaceutical said that its lead product, a once-a-day version of the widely used antibiotic amoxicillin, has failed testing for a second time. In its study of its drug in children with strep throat, it was only 65.3 percent successful, far less than the 85 percent needed to qualify as a primary treatment. Standard penicillin worked better. Advancis has about $40 million in cash and could afford more testing, but company executives said they will have to take a critical look at whether it is worth the risk.

- read this article from The Washington Post for more 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.